Despite how common GLP-1 use has become, there has been relatively little dermatology-focused research on their cutaneous side effects, with most of the existing literature limited to individual case reports. For the cross-sectional analysis, Fat and colleagues compared cutaneous adverse events reported in the FDA Adverse Event Reporting System (FAERS) for the GLP-1 receptor agonists semaglutide (Ozempic/ Wegovy, Novo Nordisk), liraglutide, exenatide and dulaglutide (Trulicity, Eli Lilly) with cutaneous adverse event reports for the dipeptidyl peptidase-4 (DPP-IV) inhibitors sitagliptin, saxagliptin, linagliptin and alogliptin
Diabetes 7 , e282e282 (2017)
Serial diluted standards resuspended in chloroform (2, 4, 8, 12, and 20 L of neutral lipid cocktail [0.25 g/L cholesteryl oleate, 0.2 g/L glyceryl trioleate, 0.15 g/L oleic acid, 0.35 g/L cholesterol]) along with 10 L per sample were loaded onto a TLC Silica Gel 60 plate (Cat
Below, we compare three direct research vendors and explain their legal status, how the peptide works in studies, the forms, fair pricing, and how to avoid scams
